111119-28-9 Usage
Uses
Used in Cell Adhesion Studies:
GLY-ARG-GLY-ASP-SER-PRO-LYS is used as a blocking peptide for inhibiting integrin-fibronectin binding in adhesion assays performed on porcine trophectoderm. This application helps researchers study the influence of transforming growth factor (TGFβ) on cell adhesion.
Used in Osteoblast Cell Research:
GLY-ARG-GLY-ASP-SER-PRO-LYS is used for incubation of MC3T3-E1 osteoblast cells to determine its effect on cell adhesion. The RGD peptide's influence on cell adhesion is measured using atomic force microscopy (AFM), providing insights into the mechanisms of cell adhesion and its regulation.
Used in Nanoparticle Preparation:
GLY-ARG-GLY-ASP-SER-PRO-LYS is used in the preparation of RGD.Flt23k.NR nanoparticles to determine the involvement of RGD-integrin bonding in the cell adhesion process. This application is significant for understanding the role of RGD peptides in cellular interactions and their potential use in targeted drug delivery and tissue engineering.
Biochem/physiol Actions
Fibronectin analog that binds to integrins.
Check Digit Verification of cas no
The CAS Registry Mumber 111119-28-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,1,1,1,1 and 9 respectively; the second part has 2 digits, 2 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 111119-28:
(8*1)+(7*1)+(6*1)+(5*1)+(4*1)+(3*9)+(2*2)+(1*8)=69
69 % 10 = 9
So 111119-28-9 is a valid CAS Registry Number.
InChI:InChI=1/C28H49N11O11/c29-8-2-1-5-16(27(49)50)37-25(47)19-7-4-10-39(19)26(48)18(14-40)38-24(46)17(11-22(43)44)36-21(42)13-34-23(45)15(35-20(41)12-30)6-3-9-33-28(31)32/h15-19,40H,1-14,29-30H2,(H,34,45)(H,35,41)(H,36,42)(H,37,47)(H,38,46)(H,43,44)(H,49,50)(H4,31,32,33)/t15-,16-,17-,18-,19-/m0/s1
111119-28-9Relevant academic research and scientific papers
Fibrinogen-coated particles for therapeutic use
-
, (2008/06/13)
The invention provides a particle comprising fibrinogen bound on the surface of an albumin matrix, wherein said particle is capable of coaggregation with platelet, and of aggregation in a solution containing soluble fibrinogen at a concentration of soluble fibrinogen not capable by it self of formation of a clot upon activation by thrombin.
Non-crosslinked protein particles for therapeutic and diagnostic use
-
, (2008/06/13)
Albumin particles in the nanometer and micrometer size range in an aqueous suspension are rendered stable against resolubilization without the aid of a crosslinking agent and without denaturation, by the incorporation of a stabilizing agent in the particle composition. Particles which are primarily albumin in the nanometer and micrometer size range in an aqueous suspension are rendered stable against resolublization by the incorporation of a reducing agent, oxidizing agent, hydrogen-accepting molecule, high molecular weight polymer, sulfur-containing ring compound or combinations thereof.
Non-crosslinked protein particles for therapeutic and diagnostic use
-
, (2008/06/13)
Albumin particles in the nanometer and micrometer size range in an aqueous suspension are rendered stable against resolubilization without the aid of a crosslinking agent and without denaturation, by the incorporation of hemoglobin in the particle composition. Particles which are primarily hemoglobin in the nanometer and micrometer size range in an aqueous suspension are rendered stable against aggregation by the incorporation of either albumin, surface active agents or gelatin.
